Begin the Phase 2 dose exploration trial of CTI-1601
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Sep 2022
- Due
- 31 Dec 2022
- Delivered
- September 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Larimar expects to begin the Phase 2 trial in Q4 2022”
What we found
Evidence strength A What the grades mean
Larimar initiated the Phase 2 dose exploration trial of CTI-1601 in September 2022, following FDA clearance, which occurred within the Q4 2022 deadline.
-
A Larimar Therapeutics, Inc. 10-K filed 2023-03-14
“In September 2022, following the Type C meeting and the submission of our complete response, the FDA allowed the 25 mg cohort of a Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in FA patients to proceed. We have since initiated the 25 mg cohort of the Phase 2 dose explor” ✓ confirmed on the page
Market reaction: the shares moved -0.7% against the S&P 500 over the three sessions around the disclosure (13 Mar 2023 to 16 Mar 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Phase 2 dose exploration trial of CTI-1601
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: FDA clearance of trial initiation
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LRMR-002937 · Corrections policy